FDA approves secukinumab for psoriatic arthritis
Novartis announced January 15 that the FDA approved Cosentyx (secukinumab) for psoriatic arthritis and active ankylosing spondylitis. The announcement comes a year after the FDA’s approval for Cosentyx for treatment of adults with moderate to severe psoriasis. The drug is the only IL-17A antagonist approved for all three indications.
See this content immediately after install